Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 4/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 12/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681691 | 0.95 | PIK3CG (0.90) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL681040 | 0.93 | PIK3CG (0.87) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL682397 | 0.93 | PIK3CG (0.86) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL15892705 | 0.91 | PIK3CG (0.83) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL681785 | 0.89 | PIK3C2B (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL680974 | 0.88 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL681964 | 0.87 | PIK3C2B (0.80) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL681724 | 0.87 | PIK3C2B (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL681734 | 0.86 | PIK3CG (0.80) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B | |
| SCHEMBL682054 | 0.86 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2346508-B1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PIK3CG 191/4885PIK3CD 147/4885PIK3CA 48/4885 |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PIK3CG 191/4885PIK3CD 147/4885PIK3CA 48/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | PIK3CG 191/4885PIK3CD 147/4885PIK3CA 48/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CG 4/4885PIK3CD 2/4885PIK3CA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.